Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Early surgery versus chemotherapy for recurrent asymptomatic glioblastoma (phase 3)
ChiCTR2000037350Phase 3Recruiting
- Sponsor
- Huashan Hospital
- Start
- Oct 2020
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of temozolomide in glioblastoma (GBM) and Gliosarcoma (GS) (2 arms), sponsored by Huashan Hospital. Primary endpoint: Median survival time. Started Oct 2020; status: recruiting.
02
Drugs
temozolomide
03
Conditions
glioblastoma (GBM)Gliosarcoma (GS)
Beyond the preview
Go deeper on ChiCTR2000037350.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000037350.